anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Arachidonic acid (AA) is involved in inflammation and plays a role in growth and brain development in infants. We previously showed that exposure of mouse sires to AA for three consecutive generations induces a cumulative change in fatty acid (FA) involved in inflammation and an increase in body and liver weight in the offspring. Here, we tested the hypothesis that paternal AA exposure changes the progeny's behavioral response to a proinflammatory insult, and asked whether tissue-specific FA are associated with that response. Male BALB/c mice were supplemented daily with three doses of AA for 10 days and crossed to non-supplemented females (n = 3/dose). Two-month-old unsupplemented male and female offspring (n = 6/paternal AA dose) were exposed to Gram-negative bacteria-derived lipopolysaccharides (LPS) or saline control two hours prior to open field test (OFT) behavioral analysis and subsequent sacrifice. We probed for significant effects of paternal AA exposure on: OFT behaviors; individual FA content of blood, hypothalamus and hypothalamus-free brain; hypothalamic expression profile of genes related to inflammation (Tnfa, Il1b, Cox1, Cox2) and FA synthesis (Scd1, Elovl6). All parameters were affected by paternal AA supplementation in a sex-specific manner. Paternal AA primed the progeny for behavior associated with increased anxiety, with a marked sex dimorphism: high AA doses acted as surrogate of LPS in males, realigning a number of OFT behaviors that in females were differential between saline and LPS groups. Progeny hypothalamic Scd1, a FA metabolism enzyme with documented pro-inflammatory activity, showed a similar pattern of differential expression between saline and LPS groups at high paternal AA dose in females, that was blunted in males. Progeny FA generally were not affected by LPS, but displayed non-linear associations with paternal AA doses. In conclusion, we document that paternal exposure to AA exerts long-term behavioral and biochemical effects in the progeny in a sex-specific manner.
A young miniature poodle was presented following blunt force trauma to the head. The dog initially responded well to medical management before developing clinical signs associated with increased intracranial pressure 48 h post-injury that became refractory to hyperosmolar therapy. A computed tomography scan obtained 76 h post-injury showed a short, oblique, non-displaced, complete fissure in the right temporal bone and a second short, oblique, non-displaced, complete fissure in the ventral aspect of the temporal bone. A biconvex, moderately hyperattenuating, space-occupying temporoparietal lesion was visualized immediately adjacent to the area of the temporal fractures. These findings were consistent with a diagnosis of intracranial extradural hematoma. Decompressive craniectomy successfully evacuated the extradural hematoma to alleviate increased intracranial pressure. The dog's neurologic function recovered quickly postoperatively. At follow-up physical examinations at 14 and 437 d, excellent return to function was noted. Key clinical message: This report describes the diagnosis and surgical management of an intracranial extradural hematoma in a dog with increased intracranial pressure refractory to medical management. Furthermore, this report describes the diagnostic imaging findings used to diagnose this particular form of primary brain injury.
BACKGROUND: Acute gastrointestinal bleeding (AGIB) is common in older patients but the use of iron in this context remains understudied.
AIMS: This study aimed to evaluate prospectively the efficacy of ferric carboxymaltose to treat anaemia in older patients after AGIB.
METHODS: This randomised double-blinded placebo-controlled clinical trial was conducted in 10 French centres. Eligible patients were 65 years or more, had controlled upper or lower gastrointestinal bleeding and a haemoglobin level of 9-11 g/dl. Patients were randomly assigned, in a 1:1 ratio, to receive either one intravenous iron injection of ferric carboxymaltose or one injection of saline solution. The primary endpoint was the difference in haemoglobin level between day 0 and day 42. Secondary endpoints were treatment-emergent adverse events, serious adverse events, rehospitalisation and improvement of quality of life (QOL) at day 180.
RESULTS: From January 2013 to January 2017, 59 patients were included. The median age of patients was 81.9 [75.8, 87.3] years. At day 42, a significant difference in haemoglobin level increase was observed (2.49 g/dl in the ferric carboxymaltose group vs. 1.56 g/dl in the placebo group, P = 0.02). At day 180, QOL, measured on European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, improved by 10.5 points in the ferric carboxymaltose group and by 8.2 points in the placebo group (P = 0.56). Rates of adverse events and rehospitalisation were similar in the two groups.
CONCLUSIONS: Intravenous iron seems safe and effective to treat anaemia in older patients after AGIB and should be considered as a standard-of-care treatment. ClinicalTrials.gov (NCT01690585).
We performed a bidirectional 2-sample Mendelian randomization (MR) design to explore the causal relation between telomere length (TL) and colorectal polyps. Genome-wide association study summary data of TL and colorectal polyps were extracted from the IEU open genome-wide association study database. Single nucleotide polymorphisms were served as instrumental variables at the significance threshold of P < 5 × 10-8. The inverse variance weighted method, MR-Egger method, and weight median method were performed for causal estimation in MR. Cochran Q test, MR-Egger intercept test, and leave-one-out analyses were performed to evaluate the pleiotropy of the MR results. One hundred and twenty-four single nucleotide polymorphisms were selected as instrumental variables. We found significant casual association between TL and colorectal polyps. Long TL increased the risk of colorectal polyps using the inverse variance weighted method [ukb-a-521: odds ratio (OR): 1.004, 95% confidence interval (CI): 1.001-1.007, P = .004; ukb-d-D12: OR: 1.008, CI: 1.004-1.012, P < .001; finn-b-CD2_BENIGN_COLORECANI_EXALLC2: OR: 1.170, CI: 1.027-1.332, P = .018]. Sensitivity analyses validated that the causality between TL and colorectal polyps was robust. The study provided a causal association between TL and colorectal polyps which indicated that TL might be served as a potential biomarker of colorectal polyps for screening and prevention. Nonetheless, the conclusions need further validation.
1. Take out the blister card. There are 21 light orange "active" pills and 7 green "reminder" pills.
  2. The blister comes to you set up for Sunday Start. If you are to start pill-taking on Sunday, take your first light orange pill on the first Sunday after your menstrual period begins. If your period begins on Sunday, take your first pill that day. Push down on the first light orange "active" pill of blister (Sunday) with your thumb or forefinger. The pill will come out through a hole in the back of the package.
  3. If you are to start pill-taking on "Day 1", the enclosed calendar label has been provided and will be placed over the calendar printed on the blister. To put label in place, identify your correct starting day of the week, locate that day label present in the calendar label and affix that day label over the printed calender on the blister. Push down on the light orange "active" pill of blister with your thumb or forefinger. The pill will come out through a hole in the back of the package.
  4. The first light orange "active" pill you will take is indicated by START and lines up with the black Day Arrow as indicated on the blister. For details, see the directions in the following picture. Continue taking one pill daily, until no pill remains by last day of the third week.



5\. The next day take the green "reminder" pill from the blister that corresponds with the day of the week it happens to be. Take a green pill each day until all seven pills are taken. During this time your period should begin.

6\. After you have taken all the green pills, begin a new blister containing blister card (see Step 1 above in "Instructions for Use") and take the first light orange "active" pill on the next day, even if your period is not yet over. 

STORAGE: Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

DETAILED PATIENT LABELING

This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against HIV infection (AIDS) and other sexually transmitted diseases.

PLEASE NOTE: This labeling is revised from time to time as important new medical information becomes available. Therefore, please review this labeling carefully.

The following oral contraceptive product contains a combination of a progestogen and estrogen, the two kinds of female hormones:

Enskyce™ (desogestrel and ethinyl estradiol) Tablets

Each light orange tablet contains 0.15 mg desogestrel and 0.03 mg ethinyl estradiol. Each green tablet contains inert ingredients.
The invention discloses a function of transcription induction spermiogenesis gene 40(Tisp40) in treatment of angiostenosis after damage and an application thereof. The application is characterized in that Tisp40 gene knockout mice and wild type mice are taken as experiment objects, through a vascular injury model, detection of mice neointima formation, vessel wall cell proliferation level and smooth muscle cell phenotype transition can be carried out. The result shows that Tisp40 gene knockout can obviously inhibit neointima formation and cell proliferation, and can inhibit transition of contractile smooth muscle cell to synthetic smooth muscle cell. The function of Tisp40 gene in angiostenosis after damage mainly embodies as promotion of neointima formation, cell proliferation and smooth muscle cell phenotype transition. By aiming at the function of Tisp40, Tisp40 can be used as a medicine target for screening the medicines for preventing, alleviating and/or treating angiostenosis after damage. A inhibitor of Tisp40 can be used for preparing the medicine and arterial stent for preventing, alleviating and/or treating angiostenosis after damage.
A syringe having 4ml of saline is used for intravenous injection. 1ml of saline is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
Colorectal cancer (CRC) arises from aberrant mutations in colorectal cells, frequently linked to chronic inflammation. This study integrated human gut metagenome analysis with an azoxymethane and dextran sulfate sodium-induced CRC mouse model to investigate the dynamics of inflammation, gut microbiota, and metabolomic profiles throughout tumorigenesis. The analysis of stool metagenome data from 30 healthy individuals and 40 CRC patients disclosed a significant escalation in both gut microbiota diversity and abundance in CRC patients compared to healthy individuals (p < 0.05). Marked structural disparities were identified between the gut microbiota of healthy individuals and those with CRC (p < 0.05), characterized by elevated levels of clostridia and diminished bifidobacteria in CRC patients (p < 0.05). In the mouse model, CRC mice exhibited distinct gut microbiota structures and metabolite signatures at early and advanced tumor stages, with subtle variations noted during the intermediate phase. Additionally, inflammatory marker levels increased progressively during tumor development in CRC mice, in contrast to their stable levels in healthy counterparts. These findings suggest that persistent inflammation might precipitate gut dysbiosis and altered microbial metabolism. Collectively, this study provides insights into the interplay between inflammation, gut microbiota, and metabolite changes during CRC progression, offering potential biomarkers for diagnosis. While further validation with larger cohorts is warranted, the data obtained support the development of CRC prevention and diagnosis strategies.
The invention relates to a food therapy preparation for preventing and treating a climacteric syndrome based on the theories of preventive treatment of disease and medicine food homology, which is characterized by comprising the effective ingredients of the following raw materials in weight ratio: 4-6 donkey-hide gelatin, 4-6 barbary wolfberry fruits, 4-6 peach seeds, 4-6 kudzu-vine roots, 4-6 of citron and 6-8 of spina date seeds. The prescription of the food therapy preparation is based on the theory of preventive treatment of disease, and the food therapy preparation is prepared from a sufficient amount effective ingredients. Although the food therapy preparation is not a medicine, the actions of the medicine can be exerted. The food therapy preparation not only can greatly limit the occurrence and the development of the climacteric syndrome, but also can save a great amount of medical resources and investments for China simultaneously. People can conveniently and correctly select the food therapy preparation in a pertinence way according to early symptoms per se to prevent the possible occurrence of climacteric syndrome, and thus, the purposes of disease prevention and body building are achieved. The food therapy preparation can be directly taken according to a certain amount, and can also be eaten together with foods and drinks as an additive of the foods and the drinks.
NEW MATERIAL:The compound of formula I (R1 is lower alkyl, alkenyl, acyl, etc.; R2 and R3 are H, lower alkyl, nitro, halogen, etc.). EXAMPLE:2-(2,4-Dichloro-5-sulfamoylbenzoyl)-1-methyl-1-phenylhydrazine. USE:Useful for the remedy of hypertension. It has mild development of the hypotensive activity and long drug action. It has extrmely low side effects such as hypokalemia, lowerong of sugar resistance, etc. caused by the diuretic action. PROCESS:The compound of formula I can be prepared by condensing the compound of formula IV with the compound of formula V in the presence of an acid acceptor, and reacting the resultant compound of formula VI with the compound of formula VII (Z is halogen).
Participants randomized to this group will be instructed based on published low-FODMAP diet guidelines and provided with sample meal plans to aid in compliance. Each participant will be randomized to low-FODMAP diet group (LFD) for 3 weeks.
1. Technical Result Increase in efficiency of neuropathologic diseases treatment.          2. Essence A pharmaceutical composition containing as an active compound 4-amino-3-substituted-butanoic acid derivative of the general formula NH2 CH2  - C - CH2 COOH R1 R2 wherein the values R1 and R2, have the values indicated in the description, humectants in pharmaceutically effective amount and pharmaceutically acceptable auxiliaries.       The composition is obtained by mixing the mentioned compound, humectant and pharmaceutically acceptable auxiliaries.         3. Field of Application Medicine.                Tables: 10
This is a form of psychoeducation involving basic discussions around mother-child relationships, childcare, child nursing related activities and general maternal discussions. The psychoeducation would last approximately 60 minutes each for 12 sessions (10 participants per sub-group). One session would be delivered every fortnight for 12 sessions.
Swaddling group: Swaddling is a wrapping procedure in which a baby's arms and legs are comfortable, sometimes only the arms are wrapped inside, and two ends of fabric are crossed on the chest of the baby, generally with thin cotton and soft fabric or a blanket. In the swaddling group, neonates were placed in the supine position on a blanket. In compliance with the newborn anatomic posture, the legs were wrapped in the flexion and abduction position. The arms of the neonates were placed close to their torso with both hands, without restraining limb movements. Swaddling was carried out 1 minute before the heel stich procedure and continued 3 minutes after the procedure. The neonate remained on the examination table during the swaddling procedure. Swaddling was applied not too loose or too tight during the procedure.
<P>PROBLEM TO BE SOLVED: To provide a method for stopping the symptoms of hardly curable athlete's foot to prevent its new infection without a special medicine.  <P>SOLUTION: A copper-containing vinegar solution obtained by immersing copper in vinegar to dissolve the copper is coated on an athlete's foot to stop the symptom of the athlete's foot. Thus, the infectious feeling of the athlete's foot is eliminated. The copper-containing vinegar solution has also actions for whitely floating the skin of the athlete's foot and for facilitating the peeling of the skin. When the copper-containing vinegar solution is coated on a healthy foot, the new infection of athlete's foot can be prevented.  <P>COPYRIGHT: (C)2003,JPO
In patients suffering from multiple trauma the initially responding emergency physician on the scene will take a blood sample for thrombelastometry immediately after i.v. access is established. According to the initial trauma life support protocols a number of patients will receive a dose of tranexamic acid during the initial treatment on the scene or during transport to the hospital. A second blood sample will be taken after arrival in the resuscitation area of the hospital. Thrombelastometric measurements will be performed with both blood samples and the extent of hyperfibrinolysis in both samples will be compared. In a second step the outcome of the patients who received tranexamic acid on the scene will be compared to those who did not receive the drug before reaching hospital.
Adolescents and young adults with PCOS and liver fat greater than or equal to 4.8% will be randomized to metformin or placebo. Metformin ER (extended release) will be administered as two pills of 500 mg each. For the first week subjects will take one pill orally on a daily basis and thereafter will take two pills orally on a daily basis. The intervention will last six months.
Thailand currently has a well-developed and robust surveillance system based on detailed mapping of all cases to the village foci level and stratification of response. In fiscal year 2019, 5,833 cases of malaria were reported with 83.0% P. vivax and 12.9% P. falciparum; nine deaths were reported. This represents a 20.8% decrease in total cases from fiscal year 2018. Currently, there are 701 "A1" villages in 44 provinces.

The research proposed here will evaluate the effectiveness and feasibility of enhanced reactive focal mass drug administration, results of which will have direct implications for continued roll out the community-led foci management, providing practical guidance that other malaria programs can utilize. Responding to the malaria among high risk populations is a requirement from the National Malaria Elimination Strategy in Thailand. Additionally, Thailand has experienced outbreaks related to forest work over the past several years, and consequently the Department of Vector Borne Disease (DVBD) is interested in introducing more aggressive parasite elimination strategies, including rfMDA for P. falciparum and P. vivax specifically targeting high-risk populations to interrupt transmission and rapidly accelerate elimination.
Targeting the endocannabinoid (eCB) signaling system for pain relief is an important treatment option that is only now beginning to be mechanistically explored. In this review, we focus on two recently appreciated cannabinoid-based targeting strategies, treatments with cannabidiol (CBD) and α/β-hydrolase domain containing 6 (ABHD6) inhibitors, which have the exciting potential to produce pain relief through distinct mechanisms of action and without intoxication. We review evidence on plant-derived cannabinoids for pain, with an emphasis on CBD and its multiple molecular targets expressed in pain pathways. We also discuss the function of eCB signaling in regulating pain responses and the therapeutic promises of inhibitors targeting ABHD6, a 2-arachidonoylglycerol (2-AG)-hydrolyzing enzyme. Finally, we discuss how the novel cannabinoid biosensor GRABeCB2.0 may be leveraged to enable the discovery of targets modulated by cannabinoids at a circuit-specific level. SIGNIFICANCE STATEMENT: Cannabis has been used by humans as an effective medicine for millennia, including for pain management. Recent evidence emphasizes the therapeutic potential of compounds that modulate endocannabinoid signaling. Specifically, cannabidiol and inhibitors of the enzyme ABHD6 represent promising strategies to achieve pain relief by modulating endocannabinoid signaling in pain pathways via distinct, nonintoxicating mechanisms of action.
A drug composition containing abiraterone acetate, and a preparation method therefor and an application thereof. Excipients thereof comprise at least one oil phase, at least one emulsifier, and at least one co-emulsifier. The dug composition can obviously improve the bioavailability and the stability of a preparation. The drug composition can be further prepared as capsules. (FIG. 4)
We propose to conduct a prospective observational study of healthcare providers to determine the accuracy of clinical assessment as compared to the assessment of pulmonary mechanics in a population of children intubated and mechanically ventilated for bronchiolitis. Before and at 20 minutes following a routinely scheduled albuterol treatment, measurements of pulmonary mechanics obtained as part of the child's clinical care will be compared to a healthcare provider's simultaneous clinical assessment. Three healthcare providers (a nurse, physician, and respiratory therapist) will assess the child during these time periods. Data regarding their observations will be recorded using a data collection tool (attached). Healthcare providers will be blinded to each other's assessments and to the measurements of pulmonary mechanics. Using sensitivity and specificity analysis, the healthcare provider's assessment of response will be compared to the standard assessment of response according to the measurements of pulmonary mechanics. A precision of the estimate of sensitivity and specificity will be calculated. Clinical characteristics of the child will be recorded. Each child may be assessed on up to three occasions if that child receives greater than 1 dose of albuterol. However, no more than 3 providers will assess the child at one time.
An apparatus for testing a wireless communication device includes a receiver, a capture module, and a control module. The receiver receives at least one test packet transmitted from the wireless communication device. The capture module captures at least a portion of the at least one test packet. The control module selectively controls the capture module to capture at least the portion based on a predetermined test flow. In one example, the at least one test packet is transmitted by the wireless communication device according to the predetermined test flow. In one example, control module selectively controls the capture module to capture at least the portion based on an expected calibration value associated with the at least one test packet. In one example, the control module selectively controls the capture module to capture at least the portion based on a predetermined value of interest.
The TF20 incorporates individual goal setting and health coaching, leveraging cultural aspects of the fire service and group cohesion to motivate behavior change. The TF20 focuses on the unique needs of FF with culturally relevant nutrition and fitness strategies. TF20 was primarily designed as a cost-effective, stand-alone program for departments which have no health promotion initiative. Program components include practical approaches to nutrition, fitness and mental health.